Navigation Links
YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
Date:1/20/2011

MISSISSAUGA, ON, Jan. 20 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, today announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea.

"The overall findings of the study are positive, and support the promise of nimotuzumab in this important global cancer market. Although not powered for statistical significance, in subgroup analyses these data demonstrated that EGFR-positive patients treated with nimotuzumab showed a potential improvement of Progression Free Survival and Overall Survival in gastric cancer. This is consistent with evidence that nimotuzumab selectively targets tissues over-expressing EGFR," said Dr. Nick Glover, President and CEO of YM BioSciences. "The authors of the study conclude that the selection of gastric cancer patients by EGFR status might be effective for future studies of nimotuzumab, and indicate that a Phase III clinical trial should be performed to examine these findings."

The results were reported in a poster being presented on January 20, 2011 at the ASCO Gastrointestinal Cancers Symposium in San Francisco, entitled: "Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results".

Trial Design and Results:

The study is a Phase II multi-center, randomized, open-label trial evaluating nimotuzumab ("N") (400 mg, IV weekly) plus irinotecan ("I") (150 mg/m2 IV every two weeks) compared to irinotecan alone in patients with advanced or recurrent gastric cancer who are refractory to a 5-fluorouracil-based regimen. The efficacy analysis was condu
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... COSTA MESA, Calif. , July 24, 2014 /PRNewswire/ ... incredibly close to home. Rehealth Regenerative Therapies , ... offering athletes and other physically active people a new ... . Regardless of age, countless patients suffer ... amateur sport activities, such as muscle tears, torn rotator ...
(Date:7/24/2014)... yet to materialise. Yet, scientists are making progress ... faster. One such approach relies on quantum dotsa ... an electric field. A new study demonstrates that ... dots (TQDs) with electrical impulses can help better ... TQDs be used as quantum information units, which ...
(Date:7/24/2014)... 24, 2014 Your cell phone ... modeling lithium-ion battery storage capacity. , New research ... theoretical model created at Lawrence Livermore National ... predicts how carbon components will perform as electrodes. ... the urgent need for higher-performance batteries. Several key ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2
... Md., July 23 SuperArray,Bioscience Corporation announced today ... moved to a brand new facility three times,larger ... its phenomenal,growth over the last few years and ... expression analysis., "We are not just a ...
... amount of retraction needed for surgical ... ... Technology,today announces the market availability of the SlimFuse(TM) Anterior,Cervical Plate System. ... addressing the clinical needs of,anterior cervical discectomy and fusion (ACDF) surgery., ...
... Del., July 23 More than a third,of ... ) to inquire about the,company,s prescription savings programs ... according to a year-long survey of more than ... of the patients who called,AstraZeneca,s information center regarding ...
Cached Biology Technology:SuperArray Bioscience Changes Name to SABiosciences and Moves Into New Larger Facility on Verge of Tenth Anniversary 2Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System 2AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 2AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 3
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, ... devices, has cut emergency room wait times by an ... (UCSD) Medical Center, according to a recent study published ... Departments are using the suite to access data from ... defibrillators. "Using Geneva,s technology platform we have ...
(Date:7/24/2014)... Invertebrate numbers have decreased by 45% on average over ... doubled, reports a study on the impact of humans ... the enormous benefits invertebrates such as insects, spiders, crustaceans, ... pollination and pest control for crops, decomposition for nutrient ... published in Science and led by UCL, ...
(Date:7/24/2014)... Los Angeles, where electric cars ply silent freeways, solar ... from beneath the earth, from howling winds and from ... finds that it is technically and economically feasible to ... clean, renewable energy. Published in Energy , the ... reliable energy supply in California that could create tens ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... NY) -- Three researchers at the Albert Einstein College ... Cancer Research Foundation (BCRF). Drs. Thomas Rohan, Susan Horwitz ... in its ongoing effort to support the advancement of ... generosity is its mission, which is to achieve prevention ...
... a Green Revolution in Africa, a renowned group of ... Africa through agricultural productivity. They will cover sustainable agriculture, ... the symposium, The African Green Revolution Takes Shape, on ... room R02 of the Ernest N. Morial Convention Center ...
... Microbes such as bacteria tend to live in complex ... cause more problems for the immune system. Biofilms comprising ... serious chronic infectious diseases such as cystic fibrosis and ... biocorrosion. Yet biofilms also have equal potential ...
Cached Biology News:Einstein researchers receive grants totaling $700,000 for innovative breast cancer research 2Now is Africa's turn for a green revolution, global experts say 2Microbial biofilms evoke Jekyll & Hyde effects 2Microbial biofilms evoke Jekyll & Hyde effects 3
...
Request Info...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
Biology Products: